HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 13; no. 9; pp. 783 - 794
• Main Authors: Valle, Blanca L, Rodriguez-Torres, Sebastian, Kuhn, Elisabetta, Díaz-Montes, Teresa, Parrilla-Castellar, Edgardo, Lawson, Fahcina P, Folawiyo, Oluwasina, Ili-Gangas, Carmen, Brebi-Mieville, Priscilla, Eshleman, James R, Herman, James, Shih, Ie-Ming, Sidransky, David, Guerrero-Preston, Rafael
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Biomarkers, Tumor - genetics; Cell Line, Tumor; Cohort Studies; Cystadenocarcinoma, Serous - diagnosis; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - mortality; Decitabine - pharmacology; Decitabine - therapeutic use; DNA Methylation - drug effects; Down-Regulation; Epithelium; Fallopian Tubes - pathology; Female; Gene Expression Regulation, Neoplastic - drug effects; Guanylate Kinases - genetics; Histones - genetics; Humans; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Mutation; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Ovary - pathology; Precision Medicine - methods; Promoter Regions, Genetic; Survival Analysis
• ISSN: 1940-6207; 1940-6215
• DOI: 10.1158/1940-6207.CAPR-19-0412

Molecular alterations that contribute to long-term (LT) and short-term (ST) survival in ovarian high-grade serous carcinoma (HGSC) may be used as precision medicine biomarkers. DNA promoter methylation is an early event in tumorigenesis, which can be detected in blood and urine, making it a feasible companion biomarker to somatic mutations for early detection and targeted treatment workflows. We compared the methylation profile in 12 HGSC tissue samples to 30 fallopian tube epithelium samples, using the Infinium Human Methylation 450K Array. We also used 450K methylation arrays to compare methylation among HGSCs long-term survivors (more than 5 years) and short-term survivors (less than 3 years). We verified the array results using bisulfite sequencing and methylation-specific PCR (qMSP). in another cohort of HGSC patient samples ( = 35). Immunoblot and clonogenic assays after pharmacologic unmasking show that and promoter methylation downregulates mRNA expression levels in ovarian cancer cells. We then used qMSP in paired tissue, ascites, plasma/serum, vaginal swabs, and urine from a third cohort of patients with HGSC cancer ( = 85) to test the clinical potential of and in precision medicine workflows. We also performed next-generation exome sequencing of 50 frequently mutated in human cancer genes, using the Ion AmpliSeqCancer Hotspot Panel, to show that the somatic mutation profile found in tissue and plasma can be quantified in paired urine samples from patients with HGSC. Our results suggest that HIST1H2BB and MAGI2 have growth-suppressing roles and can be used as HGSC precision medicine biomarkers.